Aktie 300558 BETTA PHARMACEUTICALS CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Betta Pharmaceuticals Co., Ltd.

Aktien

300558

CNE100002DD9

300558

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
41.65 CNY -2.02% Intraday Chart für Betta Pharmaceuticals Co., Ltd. -4.69% -19.20%
19.04. Betta Pharmaceuticals Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
2023 Betta Pharmaceuticals Co., Ltd. meldet Ergebnis für die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China
Betta Pharmaceuticals Co., Ltd. cancelled the transaction announced on June 13, 2022
Betta Pharmaceuticals Co., Ltd. Approves Board Elections
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300558 Aktie
  4. Nachrichten Betta Pharmaceuticals Co., Ltd.
  5. Andere Sprachen